Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival and objective response rate by cohort. b, Overall survival by cohort.
No takes yet. Share an insight, caveat, or question.
Maron et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: